文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

开发产品标签信息以支持基于证据的孕期疫苗使用

Developing product label information to support evidence-informed use of vaccines in pregnancy.
PubMed 文献 · Vaccine · 2019-10-05

该项目通过三阶段共识方法(名义群体技术会议、德尔菲调查和共识研讨会),与医疗保健提供者、疫苗监管者、行业代表及多领域专家合作,为加拿大灭活流感疫苗(IIV)和破伤风-白喉-无细胞百日咳(Tdap)疫苗产品标签制定关于孕期安全性和有效性的明确循证语言。研讨会参与者最初未意识到产品标签的监管目的是提供产品特异性临床前和临床试验数据的科学摘要。最终就标签的语言、结构和数据类型达成了强烈共识,作者认为让医疗保健提供者参与产品信息的开发和定期更新可防止导致疫苗犹豫的解读。

要点

  • 利益相关者(N=14)在名义群体技术会议中起草了产品标签声明,供德尔菲调查评估。
  • 调查参与者(N=41)对五种假设疫苗的声明提供了反馈。
  • 研讨会参与者(N=27)的讨论表明他们缺乏对产品标签监管目的的认识。

核心结论

  • 修订后的IIV和Tdap声明符合研讨会参与者的目标,即产品标签应基于证据,具有医疗保健提供者易于理解的一致结构和语言。
  • 新兴方法揭示了利益相关者对产品标签的监管目的、内容和所用证据的担忧。
  • 让医疗保健提供者参与产品信息的开发和定期更新,可防止对该信息的解读导致疫苗犹豫。

研究设计与样本

  • 三阶段共识方法项目,与利益相关者(包括医疗保健提供者、疫苗监管者、行业代表及公共卫生、传播、法律、伦理和社会科学专家)合作。
  • 使用定性和定量方法,先后举行名义群体技术(NGT)会议、德尔菲调查,然后与部分德尔菲参与者举行共识研讨会。
  • 开发了一种方法学工具来分析数据以达成共识。
  • NGT会议利益相关者N=14;德尔菲调查参与者N=41;研讨会参与者N=27。

主要发现

  • NGT会议利益相关者(N=14)起草了产品标签声明,供德尔菲调查评估。
  • 调查参与者(N=41)对五种假设疫苗的声明提供了反馈。
  • 研讨会参与者(N=27)发起的讨论表明,他们缺乏对产品标签监管目的的认识,即提供产品特异性临床前和临床试验数据的科学摘要。
  • 项目的每个阶段都建立在前一阶段的基础上,直到就利益相关者希望纳入加拿大IIV和Tdap疫苗产品标签的语言、结构和数据类型达成强烈共识。

临床怎么用

  • 作者认为,让医疗保健提供者参与产品信息的开发和定期更新,可防止对该信息的解读导致疫苗犹豫。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Product labelling information describing the use of vaccines in pregnancy continues to contain cautionary language even after clinical and epidemiological evidence of safety becomes available. This language raises safety concerns among healthcare providers who may hesitate to recommend vaccines during pregnancy. PURPOSE: To develop clear evidence-based language about vaccine safety and effectiveness in pregnancy for inclusion in vaccine product labels. METHODS: We conducted a three-stage consensus-methods project with stakeholders, including: healthcare providers, vaccine regulators, industry representatives, and experts in public health, communication, law, ethics, and social sciences. Using qualitative and quantitative methods, we held a nominal group technique (NGT) meeting, followed by a Delphi survey, and then a consensus workshop with a subset of Delphi participants. We developed a methodological tool to analyse data for consensus. PRINCIPAL RESULTS: Stakeholders (N = 14) at the NGT meeting drafted product label statements for evaluation in the Delphi survey. Survey participants (N = 41) provided feedback on statements for five hypothetical vaccines. Workshop participants (N = 27) initiated discussions that demonstrated a lack of awareness that the regulatory purpose of product labels is to provide a scientific summary of product-specific pre-clinical and clinical trial data. Each stage of this project built on earlier stages until we achieved strong consensus on the language, structure, and types of data that stakeholders wanted to include in inactivated influenza vaccine (IIV) and tetanus-diphtheria-acellular pertussis (Tdap) vaccine product labels in Canada. CONCLUSIONS: The revised statements for IIV and Tdap aligned with workshop participants' goals that the product label be evidence-based, with a consistent structure and language that is easily understood by healthcare providers. Emergent methods uncovered stakeholder concerns about the regulatory purpose, content, and evidence used in product labels. Involving healthcare providers in the development and regular updating of product information could prevent interpretations of that information that contribute to vaccine hesitancy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Manca TA, Graham JE, Dubé È, et al. Developing product label information to support evidence-informed use of vaccines in pregnancy. Vaccine. 2019. PMID: 31594709. doi:10.1016/j.vaccine.2019.09.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。